Wells Fargo analyst Brandon Couillard initiated coverage of Natera (NTRA) with an Equal Weight rating and $175 price target The firm’s enthusiasm for Signatera’s growth potential in molecular residual disease is offset by less conviction in Natera’s margin and cash flow outlook. Trading at 10-times revenue, Natera’s valuation implies a rich multiple for oncology, the analyst tells investors in a research note. Wells tells investors to wait for a better entry point.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $268 from $255 at RBC Capital
- NeoGenomics price target raised to $11 from $6.50 at Stephens
- Dell reports ‘beat and raise,’ Caterpillar sees big tariff impacts: Morning Buzz
- NeoGenomics announces court ruling in its favor in lawsuit against Natera
- Natera announces activation of ARCHER trial